Navigation Links
Cabazitaxel can offer an advantage in certain patients
Date:5/29/2012

Cabazitaxel (trade name: Jevtana) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether cabazitaxel offers an added benefit compared with the present standard therapy.

In patients aged 65 years or older and for whom further treatment with docetaxel is no longer an option, IQWiG found an indication of a considerable added benefit of cabazitaxel due to better survival prospects. In patients younger than 65 years, the data provide a "hint" of an added benefit; however, its extent cannot be precisely classified. An added benefit is not proven in patients who can still be treated with docetaxel, as adequate data are lacking.

Separate assessment for two groups of patients

In accordance with the specifications of the Federal Joint Committee (G-BA), IQWiG separately assessed the drug in two groups of patients. The G-BA has specified different appropriate comparator therapies for the two groups.

The "best supportive care population" contains patients for whom further treatment with docetaxel is no longer an option. The appropriate comparator therapy for this group is palliative treatment with dexamethasone, prednisone, prednisolone or methylprednisolone, as well as "best supportive care".

"Best supportive care" means the therapy that provides the patient with the best possible individually optimized supportive treatment to alleviate symptoms (e.g. suitable pain therapy) and improve quality of life.

The "docetaxel-retherapy population" comprises patients for whom docetaxel is still an option. The appropriate comparator therapy for this patient population i
'/>"/>

Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
49-221-356-856
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
2. Study Offers Ways to Decrease Use of Restraints at Nursing Homes
3. Prosthetic retina offers simple solution to restoring sight
4. Novel drug candidates offer new route to controlling inflammation
5. Botox Offers Little Relief for Migraine, Study Finds
6. Ice Cream Headaches Might Offer Clues to Migraines
7. Wilderness Medicine founder offers health tips for summer season
8. Here Are Fruits, Veggies That Offer Best Bang for Your Buck
9. Mayo Clinic offers newly approved treatment for acid reflux disease
10. Experts Offer Advice After Yankee Pitchers Trampoline Injury
11. Personalized immune mouse offers new tool for studying autoimmune diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Sir Fazle ... annual World Food Prize today. Sir Fazle has been recognised for his outstanding contribution ... , Ambassador Ken Quinn, President of the World Food Prize Foundation, announced this ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... retail, long term care, specialty, combo, and compounding pharmacy operations, announces the most ... to the Cardinal Health RBC event at the Venetian Las Vegas, ...
(Date:7/1/2015)... ... 2015 , ... The Collaborative for Children and Families (CCF) announced that it ... allow CCF to improve quality of care and save costs for the child welfare ... many changes in New York’s Medicaid system. Experts agree that children need thorough solutions ...
(Date:7/1/2015)... ... 2015 , ... Did you know that infertility in men is more common ... Advanced Fertility Center of Texas (AFCT) would like to talk about some natural ways ... considered to be a “woman’s issue,” male fertility factors can play a role in ...
(Date:7/1/2015)... Florida (PRWEB) , ... July 01, 2015 , ... ... for society,” said lead author Lisa Stolzenberg, a Professor in FIU’s School of ... juveniles aged 12 to 17 years who participated in the National Survey on ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced that ... at Cowen and Company,s 28th Annual Health,Care Conference on ... The,Boston Marriott Copley Place in Boston., Dr. Hung ... programs for Dimebon(TM) for Alzheimer,s and Huntington,s,diseases and MDV3100 ...
... Upcoming Federal Mandates, PORTLAND, Ore., March ... generation healthcare connectivity solutions, today announced that,Boston ... as its enterprise ePrescribing solution. This purchase, ... BMC prescribers to securely send,prescriptions from within ...
... of the Company,s, Acquisition Pipeline Gives Management Reason to Remain ... ... SAN JOSE, Calif., March 13 Pet DRx,Corporation ("Pet DRx" or ... and specialized services to companion,animals, today affirmed its 2008 guidance, noting ...
... Execution of Partnership Strategy Provides Nearly $450 Million ... and Committed Cash * 2008 Projected Net Operating Loss Less ... than $450 Million * Conference Call Webcast Thursday, March 13, 08:30 a.m. EDT ... http://www.isispharm.com , CARLSBAD, Calif., March 13 ...
... combination therapy VELCADE, melphalan and prednisone, reported a 32 percent complete ... ... years --, CAMBRIDGE, Mass., March 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: ... Phase I/II clinical trial of the combination therapy,VELCADE, melphalan and prednisone ...
... 13 Echo Therapeutics,(OTC Bulletin Board: ECTE) ... of the Symphony(TM) tCGM System, a novel, ... at the,Tufts Medical Center in Boston, Massachusetts ... to provide patients with diabetes and healthcare,professionals ...
Cached Medicine News:Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 2Health News:Boston Medical Center Meets Prescription Challenges With Kryptiq ePrescribing Solution 3Health News:Pet DRx Affirms 2008 Guidance 2Health News:Pet DRx Affirms 2008 Guidance 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 2Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 3Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 4Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 5Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 6Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 7Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 8Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 9Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 10Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 11Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 12Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 13Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 14Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 15Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 16Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 17Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 18Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 19Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 20Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 21Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 22Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 23Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 24Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 25Health News:Isis Reports Financial Results and Highlights for Fiscal year 2007 26Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 2Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 3Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 4Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 5Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 6Health News:Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients 7
(Date:7/1/2015)... 2015 The Coalition of State Rheumatology ... regional professional rheumatology societies, today released the findings ... perceptions of biosimilars and the potential impact of ... Biosimilars are medicines that are highly similar, but ... different from generic medications in that it is ...
(Date:7/1/2015)... 2015 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... presentation at the Cantor Fitzgerald Healthcare Conference in ... Russell Cox , executive vice president and chief operating ... business and financial update on Wednesday, July 8, 2015 at ... A live audio webcast of the presentation may be accessed ...
(Date:7/1/2015)... 2015 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... taking place in New York, NY ... Hotel. James Sapirstein , Chief ... business during his live presentation and will be available ...
Breaking Medicine Technology:Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Jazz Pharmaceuticals to Present at Cantor Fitzgerald Healthcare Conference on July 8 2ContraVir to Present at Cantor Fitzgerald Inaugural Healthcare Conference 2
... HILLS, Calif., Sept. 15, 2011 HealthTech Capital, a ... emerging HealthTech market, announced today that it has closed ... from HealthTech Capital members in a Series B syndicated ... while Niveus Medical received $600,000 in a Series A ...
... Sept. 15, 2011 CarePoint Partners (CarePoint), a leading ... that it has acquired Mountain State Infusion Services (Mountain ... 14th acquisition in less than four years. CarePoint now ... and is one of the largest independent infusion therapy ...
Cached Medicine Technology:HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 2HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market 3CarePoint Partners Expands Coverage in the Ohio Valley Region with Acquisition of Mountain State Infusion Services 2
Inquire...
Inquire...
... anti-reflux valve is enclosed in ... prevents the valve from being ... sitting or reclining positions. The ... interference free ensuring uninterrupted flow ...
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Medicine Products: